Hande TURAN, Gürkan TARÇIN, Aydilek DAĞDEVİREN ÇAKIR, Didem GÜNEŞ KAYA, Yavuz ÖZER, Oya ERCAN, Saadet Olcay EVLİYAOĞLU

Assessment of two different insulin regimens in children with type 1 diabetes: A longitudinal study

Aim: In type 1 diabetes, insulin therapy can be applied by either daily multiple dose injections with an insulin pen or subcutaneous continuous insulin infusion with an insulin pump. Numerous studies have investigated the superiority of both regimens over each other, and conflicting results have been reported. In this study, the periods when patients with type 1 diabetes were receiving subcutaneous continuous insulin infusion and multiple dose injections were compared in terms of clinical and metabolic outcomes. Materials and Methods: Children with type 1 diabetes who were receiving multiple dose injections and later switched to subcutaneous continuous insulin infusion were included. Follow-up period was evaluated in two periods: during multiple dose injections and subcutaneous continuous insulin infusion. Physical and laboratory findings, blood sugar monitoring and food chart records were compared between these two periods. Results: A total of 44 cases with a mean age of 10.6± 4.4 years were included. While a significant decrease was found in HbA1C values in the first year after the insertion of insulin pump, the values in the second year were similar to that in the pre-pump period. Mean body mass index was increased after switching to subcutaneous continuous insulin infusion. In the second year of the subcutaneous continuous insulin infusion, a significant decrease in hypoglycemic events was observed. Conclusion: In terms of glycemic control, no difference was found between subcutaneous continuous insulin infusion and multiple dose injections in the long term suggesting that similar clinical results can be obtained with multiple dose injections therapy in cases who cannot afford an insulin pump. Considering that HbA1c levels tend to increase in the second year of subcutaneous continuous insulin infusion and similarly body mass index after switching to subcutaneous continuous insulin infusion, clinicians should be aware of the misuse of insulin pump, and patients’ education should be revised regularly.

PDF

___

1. International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium. Atlas de la Diabetes de la FID. 2019.
2. Ye¸silkaya E, Cinaz P, Andıran N, et al. First report on the nationwide incidence and prevalence of Type 1 diabetes among children in Turkey. Diabetic Medicine [Internet]. 2017 Mar;34(3):405–10.
3. Nathan DM. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care [Internet]. 2014 Jan 19;37(1):9–16.
4. Chiang JL, Kirkman MS, Laffel LMB, et al., Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes care [Internet]. 2014 Jul;37(7):2034–54.
5. Doyle EA, Weinzimer SA, Steffen AT, et al. A Randomized, Prospective Trial Comparing the Efficacy of Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections Using Insulin Glargine. Diabetes Care [Internet]. 2004 Jul 1;27(7):1554–8.
6. Bruttomesso D, Costa S, Baritussio A. Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy. Diabetes/Metabolism Research and Reviews [Internet]. 2009 Feb;25(2):99– 111.
7. Clements MA, Foster NC, Maahs DM, et al. Hemoglobin A1c (HbA1c) changes over time among adolescent and young adult participants in the T1D exchange clinic registry. Pediatric Diabetes [Internet]. 2016 Aug;17(5):327–36.
8. Jakisch BI, Wagner VM, Heidtmann B, et al. Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years. Diabetic Medicine [Internet]. 2008 Jan 10;25(1):80–5.
9. Benkhadra K, Alahdab F, Tamhane SU, et al. Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: a systematic review and meta-analysis. Endocrine [Internet]. 2017 Jan 1;55(1):77–84.
10. AbdulRasoul M, Mousa M, Al-Mahdi M, et al. A Comparison of Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Insulin Injection in Children with Type I Diabetes in Kuwait: Glycemic Control, Insulin Requirement, and BMI. Oman Medical Journal [Internet]. 2015 Sep 15;3(5):336–43.
11. Özen S, Gök¸sen D, Demir G, et al. Insulin Pump Therapy: Its Effect on Metabolic Control in Different Age Groups in Children with Type 1 Diabetes. The Journal of Pediatric Research [Internet]. 2014 Sep 5;1(3):147– 51.
12. DiMeglio LA, Acerini CL, Codner E, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatric Diabetes [Internet]. 2018 Oct;19:105–14.
13. Donaghue KC, Marcovecchio ML, Wadwa RP, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Microvascular and macrovascular complications in children and adolescents. Pediatric Diabetes [Internet]. 2018 Oct;19:262–74.
14. Karges B, Schwandt A, Heidtmann B, et al. Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes. JAMA [Internet]. 2017 Oct 10;318(14):1358.
15. Misso ML. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Journal of EvidenceBased Medicine [Internet]. 2010 Aug;3(3):186–186.
16. Abaci A, Atas A, Unuvar T, et al.. A Comparison of Multiple Daily Insulin Therapy with Continuous Subcutaneous Insulin Infusion Therapy in Adolescents with Type 1 Diabetes Mellitus: A Single-Center Experience From Turkey. Journal of Pediatric Endocrinology and Metabolism [Internet]. 2009 Jan;22(6).
17. Mameli C, Scaramuzza AE, Ho J, et al. A 7-year follow-up retrospective, international, multicenter study of insulin pump therapy in children and adolescents with type 1 diabetes. Acta Diabetologica [Internet]. 2014 Apr 17;51(2):205–10.
18. Pickup J, Keen H. Continuous Subcutaneous Insulin Infusion at 25 Years: Evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care [Internet]. 2002 Mar 1;25(3):593–8.
19. Blair JC, McKay A, Ridyard C, et al. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation. BMJ [Internet]. 2019 Apr 3;l1226.
20. Miyawaki J, Sakayama K, Kato H, et al. Perinatal and Postnatal Exposure to Bisphenol A Increases Adipose Tissue Mass and Serum Cholesterol Level in Mice. Journal of Atherosclerosis and Thrombosis [Internet]. 2007;14(5):245–52.
21. Battelino T. Risk and benefits of continuous subcutaneous insulin infusion (CSII) treatment in school children and adolescents. Pediatric Diabetes. 2006.
22. Johnson SR, Cooper MN, Jones TW, et al. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case–control study. Diabetologia [Internet]. 2013 Nov 21;56(11):2392–400.
23. Ahern JAH, Boland EA, Doane R, et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatric Diabetes [Internet]. 2002 Mar;3(1):10–5.
24. Hathout EH, McClintock T, Sharkey J, et al. Glycemic, Auxologic, and Seasonal Aspects of Continuous Subcutaneous Insulin Infusion Therapy in Children and Young Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics [Internet]. 2003 Apr;5(2):175–81.
25. Fendler W, Baranowska AI, Mianowska B, et al. Three-year comparison of subcutaneous insulin pump treatment with multi-daily injections on HbA1c, its variability and hospital burden of children with type 1 diabetes. Acta Diabetologica [Internet]. 2012 Oct 1;49(5):363–70.
26. Hanas R, Adolfsson P. Insulin pumps in pediatric routine care improve long-term metabolic control without increasing the risk of hypoglycemia. Pediatric Diabetes [Internet]. 2006 Feb;7(1):25–31.
27. Alderisio A, Bozzetto L, Franco L, et al. Long-term body weight trajectories and metabolic control in type 1 diabetes patients on insulin pump or multiple daily injections: A 10-year retrospective controlled study. Nutrition, Metabolism and Cardiovascular Diseases [Internet]. 2019 Oct;29(10):1110–7.
28. Prídavková D, Samoš M, Kazimierová I, et al. Insulin Pump Therapy – Influence on Body Fat Redistribution, Skeletal Muscle Mass and Ghrelin, Leptin Changes in T1D Patients. Obesity Facts [Internet]. 2018;11(6):454– 64.
29. Raile K, Noelle V, Landgraf R, et al. Weight in Adolescents with Type 1 Diabetes Mellitus During Continuous Subcutaneous Insulin Infusion (CSII) Therapy. Journal of Pediatric Endocrinology and Metabolism [Internet]. 2002 Jan;15(5).
30. Willi SM, Planton J, Egede L, et al. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. The Journal of Pediatrics [Internet]. 2003 Dec;143(6):796–801.
31. Bin-Abbas B, Al-Ashwal A, Sakati N. Continuous subcutaneous insulin infusion in type 1 diabetic Saudi children: a comparison with multiple daily insulin injections. Ann Saudi Med. 2006;26(4):327–8.
32. Deiss D, Hartmann R, Hoeffe J, et al. Assessment of glycemic control by continuous glucose monitoring system in 50 children with type 1 diabetes starting on insulin pump therapy. Pediatric Diabetes [Internet]. 2004 Sep;5(3):117–21.
33. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes care [Internet]. 2019;42(8):1593–603.
34. Jeitler K, Horvath K, Berghold A, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia [Internet]. 2008 Jun 20;51(6):941–51.
35. Johannesen J, Eising S, Kohlwes S, et al. Treatment of Danish adolescent diabetic patients with CSII - a matched study to MDI. Pediatric Diabetes [Internet]. 2008 Jan 16;9(1):23–8.
36. Steindel BS, Roe TR, Costin G, et al. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. Diabetes research and clinical practice [Internet]. 1995 Mar;27(3):199–204.
37. Shalitin S, Gil M, Nimri R, et al. Predictors of glycaemic control in patients with Type 1 diabetes commencing continuous subcutaneous insulin infusion therapy. Diabetic Medicine [Internet]. 2010 Mar;27(3):339–47